CO6970603A2 - Composiciones y métodos para tratar el virus de la hepatitis c - Google Patents

Composiciones y métodos para tratar el virus de la hepatitis c

Info

Publication number
CO6970603A2
CO6970603A2 CO14121393A CO14121393A CO6970603A2 CO 6970603 A2 CO6970603 A2 CO 6970603A2 CO 14121393 A CO14121393 A CO 14121393A CO 14121393 A CO14121393 A CO 14121393A CO 6970603 A2 CO6970603 A2 CO 6970603A2
Authority
CO
Colombia
Prior art keywords
virus
compositions
methods
treat hepatitis
hepatitis
Prior art date
Application number
CO14121393A
Other languages
English (en)
Spanish (es)
Inventor
Darryl G Cleary
Charles Reynolds
Miriam Michelle Berrey
Robert Hindes
William T Symonds
Adrian S Ray
Hongmei Mo
Christy Hebner
Reza Oliyai
Vahid Zia
Dimitrios Stefanidis
Melissa Jean Casteel
Original Assignee
Gilead Pharmassett Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56291296&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6970603(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2012/055621 external-priority patent/WO2013040492A2/en
Priority claimed from US13/661,509 external-priority patent/US20130109647A1/en
Application filed by Gilead Pharmassett Llc filed Critical Gilead Pharmassett Llc
Publication of CO6970603A2 publication Critical patent/CO6970603A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CO14121393A 2011-11-29 2014-06-05 Composiciones y métodos para tratar el virus de la hepatitis c CO6970603A2 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161564500P 2011-11-29 2011-11-29
PCT/US2012/055621 WO2013040492A2 (en) 2011-09-16 2012-09-14 Methods for treating hcv
US201261707459P 2012-09-28 2012-09-28
US13/661,509 US20130109647A1 (en) 2011-10-31 2012-10-26 Methods and compositions for treating hepatitis c virus

Publications (1)

Publication Number Publication Date
CO6970603A2 true CO6970603A2 (es) 2014-06-13

Family

ID=56291296

Family Applications (1)

Application Number Title Priority Date Filing Date
CO14121393A CO6970603A2 (es) 2011-11-29 2014-06-05 Composiciones y métodos para tratar el virus de la hepatitis c

Country Status (21)

Country Link
EP (2) EP3777867A1 (enExample)
JP (2) JP5899327B2 (enExample)
KR (1) KR101560994B1 (enExample)
CN (1) CN104039319B (enExample)
AR (1) AR089578A1 (enExample)
AU (1) AU2012346217B2 (enExample)
BR (1) BR112014012739A8 (enExample)
CA (1) CA2856529C (enExample)
CO (1) CO6970603A2 (enExample)
EA (1) EA027296B1 (enExample)
EC (1) ECSP14005678A (enExample)
ES (1) ES2817886T3 (enExample)
MD (1) MD4430C1 (enExample)
MX (1) MX2014006373A (enExample)
PE (1) PE20141296A1 (enExample)
PH (1) PH12014501133B1 (enExample)
SG (1) SG11201402609RA (enExample)
TW (1) TWI566773B (enExample)
UY (1) UY34474A (enExample)
WO (1) WO2013082003A1 (enExample)
ZA (1) ZA201404061B (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20180237T4 (hr) 2011-09-16 2020-12-11 Gilead Pharmasset Llc Metode za liječenje hcv-a
EP2950786B1 (en) 2013-01-31 2019-11-27 Gilead Pharmasset LLC Combination formulation of two antiviral compounds
US20170080008A1 (en) * 2014-03-05 2017-03-23 Galenicum Health S.L. Stable pharmaceutical compositions of sofosbuvir
SI3154526T1 (sl) 2014-06-13 2019-08-30 Ratiopharm Gmbh Trdne oblike sofosbuvira
WO2015197549A1 (en) * 2014-06-23 2015-12-30 Sanovel Ilac Sanayi Ve Ticaret A.S. A novel pharmaceutical composition of sofosbuvir and ribavirin
EP2959891A1 (en) * 2014-06-23 2015-12-30 Sanovel Ilac Sanayi ve Ticaret A.S. Modified release pharmaceutical compositions of sofosbuvir and ribavirin
EP2959901A1 (en) * 2014-06-23 2015-12-30 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of sofosbuvir and ribavirin
CN105267232A (zh) * 2014-06-30 2016-01-27 康普药业股份有限公司 一种用于治疗丙型肝炎的药物制剂及其制备方法
WO2016035006A1 (en) * 2014-09-01 2016-03-10 Dr. Reddy’S Laboratories Limited Novel nucleotide analogs, process for the preparation of sofosbuvir and its analogs, novel forms of sofosbuvir and solid dispersion of sofosbuvir
US20170296570A1 (en) * 2014-10-08 2017-10-19 Sandoz Ag High Drug Load Tablets Comprising Sofosbuvir
CN104546783A (zh) * 2014-12-12 2015-04-29 安徽一灵药业有限公司 一种索非布韦薄膜包衣片制剂及其制备方法
CN104622836B (zh) * 2014-12-23 2020-02-21 浙江华海药业股份有限公司 索非布韦包衣片剂及其制备方法
WO2016106050A1 (en) 2014-12-26 2016-06-30 Emory University N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CN104586802B (zh) * 2015-02-02 2018-01-16 长春海悦药业股份有限公司 一种含有索菲布韦的药物组合物
WO2016156330A1 (en) * 2015-03-30 2016-10-06 Ratiopharm Gmbh Solid pharmaceutical composition comprising amorphous sofosbuvir and a phospholipid
CN104840964B (zh) * 2015-05-07 2018-01-16 南京正大天晴制药有限公司 一种稳定的索氟布韦药物组合物及其制备方法
CZ2015443A3 (cs) 2015-06-26 2017-01-04 Zentiva, K.S. Farmaceutická formulace sofosbuviru
CN104906062B (zh) * 2015-06-30 2018-05-25 浙江天顺生物科技有限公司 一种索非布韦的片剂及其制备方法
JOP20170127A1 (ar) * 2016-06-02 2017-12-02 Gilead Pharmasset Llc صيغة مشتركة مكونة من ثلاث مركبات مضادة للفيروسات
MX2019002017A (es) 2016-08-19 2019-06-06 Sandoz Ag Derivados de sofosbuvir para el tratamiento de la hepatitis c.
CZ2016553A3 (cs) 2016-09-09 2018-03-21 Zentiva, K.S. Pevná farmaceutická dávková forma obsahující sofosbuvir
CN106667936B (zh) * 2016-12-31 2021-02-05 江苏科本药业有限公司 一种索非布韦片剂及其制备方法
CN107041873B (zh) * 2017-02-17 2020-02-28 杭州青玥医药科技有限公司 索氟布韦包衣片剂的制备方法
CN106880642B (zh) * 2017-02-17 2019-08-06 杭州青玥医药科技有限公司 索氟布韦药物组合物及其制备方法
RU2020116571A (ru) 2017-12-07 2021-11-22 Эмори Юниверсити N4-гидроксицитидин и производные и связанные с этим противовирусные применения
KR20200043618A (ko) 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
CN110604726B (zh) * 2019-07-19 2022-06-07 株洲千金药业股份有限公司 一种索非布韦组合物及其应用
CN111072742B (zh) * 2019-12-23 2022-12-02 南京正大天晴制药有限公司 一种治疗丙肝药物的新晶型及其组合物
CN111973566A (zh) * 2020-07-23 2020-11-24 石药集团中奇制药技术（石家庄）有限公司 一种索磷布韦片
CN114796144A (zh) * 2021-01-29 2022-07-29 北京澳合药物研究院有限公司 一种索非布韦药物组合物及其制备方法和其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4530901A (en) 1980-01-08 1985-07-23 Biogen N.V. Recombinant DNA molecules and their use in producing human interferon-like polypeptides
IL154306A0 (en) * 2003-02-05 2003-09-17 Rimonyx Pharmaceuticals Ltd Pharmaceutical compositions comprising thieno [2,3-c] pyridine derivatives and use thereof
US7816326B2 (en) * 2004-02-27 2010-10-19 Schering Corporation Sulfur compounds as inhibitors of hepatitis C virus NS3 serine protease
EP2125113A2 (en) * 2007-02-26 2009-12-02 Achillion Pharmaceuticals, Inc. Tertiary amine substituted peptides useful as inhibitors of hcv replication
US7964580B2 (en) 2007-03-30 2011-06-21 Pharmasset, Inc. Nucleoside phosphoramidate prodrugs
CA2699280A1 (en) 2007-09-14 2009-03-26 Schering Corporation Method of treating hepatitis c patients
DE102007052070A1 (de) * 2007-10-30 2009-05-07 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Candesartancilexetil
DE102008057284A1 (de) * 2008-11-14 2010-05-20 Ratiopharm Gmbh Tabletten enthaltend Lenalidomid und Adhäsionsverstärker
JP5689810B2 (ja) * 2008-11-20 2015-03-25 アキリオン ファーマシューティカルズ，インコーポレーテッド Ｃ型肝炎ウイルス用の環状カルボキサミド化合物およびその類似体
DE102009015702A1 (de) * 2009-03-31 2010-10-07 Ratiopharm Gmbh Tabletten enthaltend Dapoxetin und Trockenverarbeitungsverfahren zu deren Herstellung
US8618076B2 (en) 2009-05-20 2013-12-31 Gilead Pharmasset Llc Nucleoside phosphoramidates
TWI576352B (zh) * 2009-05-20 2017-04-01 基利法瑪席特有限責任公司 核苷磷醯胺
EP2467144A1 (en) * 2009-07-24 2012-06-27 ViroLogik GmbH Combination of proteasome inhibitors and anti-hepatitis medication for treating hepatitis
AP2012006535A0 (en) * 2010-03-31 2012-10-31 Gilead Pharmasset Llc Stereoselective synthesis of phosphorous containing actives
US20120107278A1 (en) 2010-10-29 2012-05-03 Pharmasset, Inc. Abbreviated hcv therapy for hcv infected patients with il28b c/c genotype

Also Published As

Publication number Publication date
TW201325599A (zh) 2013-07-01
NZ625532A (en) 2016-07-29
ES2817886T3 (es) 2021-04-08
EP2785340A1 (en) 2014-10-08
ZA201404061B (en) 2016-09-28
EA027296B1 (ru) 2017-07-31
JP2016053096A (ja) 2016-04-14
KR101560994B1 (ko) 2015-10-15
CA2856529A1 (en) 2013-06-06
AR089578A1 (es) 2014-09-03
MD20140058A2 (en) 2014-11-30
MD4430B1 (ro) 2016-08-31
MX2014006373A (es) 2014-07-22
JP5899327B2 (ja) 2016-04-06
BR112014012739A8 (pt) 2017-06-20
KR20140108645A (ko) 2014-09-12
CN104039319B (zh) 2017-12-29
CA2856529C (en) 2018-03-06
PH12014501133A1 (en) 2014-09-01
PH12014501133B1 (en) 2014-09-01
PE20141296A1 (es) 2014-10-08
CN104039319A (zh) 2014-09-10
SG11201402609RA (en) 2014-06-27
WO2013082003A1 (en) 2013-06-06
EP3777867A1 (en) 2021-02-17
UY34474A (es) 2013-06-28
EA201490903A1 (ru) 2014-11-28
ECSP14005678A (es) 2015-12-31
JP2014533733A (ja) 2014-12-15
TWI566773B (zh) 2017-01-21
AU2012346217A1 (en) 2014-06-19
EP2785340B1 (en) 2020-07-15
MD4430C1 (ro) 2017-03-31
BR112014012739A2 (pt) 2017-06-13
HK1202268A1 (en) 2015-09-25
AU2012346217B2 (en) 2016-02-04

Similar Documents

Publication Publication Date Title
IL269662A (en) Hepatitis C virus inhibitors
BR112014006324A2 (pt) método para tratar hcv
IL262123A (en) Influenza virus vaccines and uses thereof
CL2015001157A1 (es) Composiciones y métodos para tratar proteinopatías.
ES2579990T8 (es) Métodos y composiciones para tratar el síndrome metabólico
BR112014000787A2 (pt) método para produzir vírus vaccinia
SG11201402609RA (en) Compositions and methods for treating hepatitis c virus
PL2704737T3 (pl) Terapeutyczne kompozycje nukleaz i sposoby
CO6940439A2 (es) Composiciones plaguicidas y procesos relacionados con dichas composiciones
IL227789A0 (en) Hepatitis c virus inhibitors
BR112013019732A2 (pt) composições e métodos para tratamento de doenças cardiovasculares
IL232780A0 (en) Influenza virus vaccines and uses thereof
LT2704703T (lt) Transderminės ibuprofeno kompozicijos ir jų naudojimo būdai
IL229270A0 (en) Hepatitis c virus inhibitors
CO6890100A2 (es) Tratamientos de combinación para hepatitis c
IL225853A0 (en) Inhibitors of hepatitis c virus
CO6940424A2 (es) Inhibidores del virus de la hepatitis c
CO6821952A2 (es) Inihibidores del virus de la hepatitis c
EP2706992A4 (en) DEFENSIVE EFFECT OF PTEROSTILS
PL3400958T3 (pl) Kompozycje i metody leczenia celiakii
CL2015000140A1 (es) Composiciones y método para controlar las poblaciones de plagas de fitoparásitos
EP2852662A4 (en) HERPESVIRUS COMPOSITIONS AND RELATED METHODS
BR112012027834A2 (pt) método para produzir macarrão instântaneo e macarrão instântaneo
CO6801768A2 (es) Procesos para la preparación de inhibidores del virus de la hepatitis
BR112013022530A2 (pt) método terapêutico homeopático e composições

Legal Events

Date Code Title Description
FC Application refused